Barclays raised the firm’s price target on Neurocrine to $135 from $125 and keeps an Overweight rating on the shares. The analyst updated the company’s model into Q4. The firm sees a “positive catalyst setup” and reiterates a favorable bias into Neurocrine’s focal onset seizures data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine presenting post hoc data analysis in congenital adrenal hyperplasia
- Biotech Alert: Searches spiking for these stocks today
- Neurocrine’s NDA for Ingrezza granules accepted by FDA
- Neurocrine price target raised to $152 from $148 at Baird
- Neurocrine price target raised to $144 from $132 at Canaccord